Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High Following Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week high on Tuesday after Raymond James Financial upgraded the stock from an outperform rating to a strong-buy rating. Raymond James Financial now has a $123.00 price target on the stock, up from their previous price target of $63.00. Dianthus Therapeutics traded as high as $84.86 and last traded at $79.23, with a volume of 4610745 shares changing hands. The stock had previously closed at $65.20.

A number of other analysts have also issued reports on the stock. Wedbush increased their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday. HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research report on Monday. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday. Robert W. Baird increased their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the phase 3 CAPTIVATE CIDP trial after an interim responder analysis — company met GO criteria with 20 confirmed responders and will keep the Part A dose, accelerating development and creating a near‑term catalyst (top‑line CIDP data expected year‑end 2026). Globe Newswire — Early GO Decision
• Positive Sentiment: Encouraging clinical update drove sharp intraday gains — multiple outlets report shares jumped after the interim data and management commentary indicating the program is advancing (investor enthusiasm for a late‑stage autoimmune asset). Investing.com — Stock Surges on CIDP Trial Success
• Positive Sentiment: Multiple analyst upgrades and big price‑target increases (Raymond James to strong‑buy/$123, Robert W. Baird to $132, HC Wainwright to $130, Truist to $110, Guggenheim reiteration) are reinforcing bullish sentiment and providing supporting coverage. Yahoo Finance — Guggenheim Reiterates Buy
• Neutral Sentiment: Analyses and writeups are re‑examining DNTH valuation after large share gains (12–13x over two years); these pieces help frame risk/reward but don’t change near‑term fundamentals. Investors.com — What’s Going On?
• Neutral Sentiment: Company disclosed an AI integration-related cyber/privacy/reputational risk in filings — worth monitoring operationally but not an immediate stock driver versus clinical and financing news. TipRanks — AI Integration Risk
• Negative Sentiment: Announced proposed $400M underwritten public offering (plus 30‑day option for up to $60M) — dilutive capital raise that triggered a stock pullback as investors weigh share issuance against cash runway and program funding. Globe Newswire — $400M Offering
• Negative Sentiment: Q4 earnings missed consensus (loss of $1.43 vs. est. ~$0.97), highlighting ongoing operating losses and the company’s need for external funding — a reminder that clinical progress, not current revenue, is the primary value driver. Zacks — Q4 Loss, Miss

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP lifted its stake in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. State Street Corp lifted its stake in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after acquiring an additional 836,571 shares during the last quarter. Braidwell LP bought a new stake in Dianthus Therapeutics in the third quarter worth approximately $32,859,000. Finally, Polar Capital Holdings Plc acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth $29,434,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

The company has a market cap of $3.76 billion, a price-to-earnings ratio of -21.20 and a beta of 1.56. The company’s 50 day moving average price is $50.09 and its 200 day moving average price is $41.61.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 41.34%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.